BridgeBio Oncology Therapeutics ... Myers Squibb, the Mirati acquisition that brought Krazati included another drug candidate in early clinical development for KRAS G12D-mutated solid tumors.

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

That is ASP3082, a novel protein degrader that targets mutated KRAS G12D and follows in the footsteps ... be approved by the FDA in 2021, as well as Mirati’s Krazati (adagrasib).

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics ... lines with different KRAS mutation profiles: In AsPC-1 (harboring KRAS G12D mutation): ~70% reduction ...

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

Silexion Therapeutics Corp. SLXN released ... pancreatic cancer cell lines with different KRAS mutation profiles: In AsPC-1 (harboring KRAS G12D mutation): ~70% reduction in overall ...

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ ... Key New Findings In AsPC-1 (harboring KRAS G12D mutation): ~70% reduction in overall ...

(RTTNews) - Silexion Therapeutics ... KRAS mutation profiles. In particular, the treatment resulted in: -- A ~70 percent reduction in tumor cell numbers in the AsPC-1 model (KRAS G12D mutation).

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.

Silexion Therapeutics Corp. announced ... pancreatic cancer cell lines with different KRAS mutation profiles: In AsPC-1 (harboring KRAS G12D mutation): ~70% reduction in overall bioluminescence ...

The new results invited immediate comparisons with the KRYSTAL-1 study of Mirati Therapeutics' adagrasib – Amgen's closest rival in the KRAS inhibitor category – which were reported last month.